Newsroom | 39200 results
Sorted by: Latest
-
BioRewards Plasma Services and Alpha-1 Plasma Holdings Launch $100M Expansion Plan to Revolutionize Plasma Collection
NEW YORK--(BUSINESS WIRE)--BioRewards and Alpha-1 launch $100M blood plasma collection center venture to meet rising global demand for plasma-derived therapies....
-
SBC Medical Group Holdings gibt Finanzergebnisse für das erste Quartal 2025 bekannt
IRVINE, Kalifornien, USA--(BUSINESS WIRE)--Die SBC Medical Group Holdings Incorporated (NASDAQ: SBC, „SBC Medical“ oder „Unternehmen“), ein weltweit tätiger Eigner, Betreiber und Anbieter von Management-Services und Produkten für kosmetische Behandlungszentren, hat heute seine Finanzergebnisse für das am 31. März 2025 abgeschlossene Quartal veröffentlicht. Highlights des ersten Quartals 2025 Der Gesamtumsatz belief sich auf 47 Millionen US-Dollar – ein Rückgang von 14 % im Vergleich zum Vorjahr...
-
Acuitas Therapeutics Showcases Collaboration with Children’s Hospital of Philadelphia for Personalized CRISPR Therapy and New LNP Research at ASGCT 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)--Acuitas’ LNP enabled delivery of three doses of a personalized CRISPR therapy with no adverse events to an infant patient with urea cycle disorder...
-
Clinical Diagnostics Automation Research Business Report 2025: Global Market to Reach $8.3 Billion by 2030 - Growth in Molecular Diagnostics Strengthens Business Case for Automation - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Clinical Diagnostics Automation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Clinical Diagnostics Automation was valued at US$5.7 Billion in 2024 and is projected to reach US$8.3 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decis...
-
Colbeck Capital Supports World NF Awareness Day and the Children’s Tumor Foundation
NEW YORK--(BUSINESS WIRE)--Colbeck Capital Management, a leading middle-market private credit firm focused on strategic lending, today announced its continued support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) in recognition of World NF Awareness Day which brings global attention to neurofibromatosis and schwannomatosis (collectively known as NF), a group of genetic conditions that cause tumors to grow on nerves throughout the body. World NF Awareness Day takes place annuall...
-
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data from Part 2 of the EMBARK study that continue to support the clinical benefits of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy. These data are among other ELEVIDYS data from Sarepta’s portfolio presented during the 28th annual meeting of the American Society...
-
SBC Medical Group Holdings annonce ses résultats financiers pour le premier trimestre 2025
IRVINE, Californie--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (NASDAQ : SBC, « SBC Medical » ou la « société »), propriétaire, opérateur et fournisseur mondial de services de gestion et de produits pour les centres de soins esthétiques, a annoncé aujourd’hui ses résultats financiers pour les trois mois se terminant le 31 mars 2025. Chiffres du premier trimestre 2025 Le chiffre d’affaires total s’est élevé à 47 millions de dollars, soit une baisse de 14 % d’une année sur l’autre....
-
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment of patients with non-segmental vitiligo in China. Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related au...
-
SBCメディカルグループホールディングス株式会社、2025年第1四半期決算を発表(参考和訳版)
米カリフォルニア州 アーバイン--(BUSINESS WIRE)--（ビジネスワイヤ） -- SBC Medical Group Holdings Incorporated（以下「SBCメディカル」、または「当社」）は本日、グローバルな美容医療クリニック向けのサービスプロバイダーとして、2025年3月31日を期末とする第1四半期の決算を発表した。 2025年第1四半期ハイライト 売上高は47百万ドルで、前年同期から14％減少した。 営業利益は24百万ドルで、前年同期から1％減少した。 当社株主に帰属する四半期純利益は22百万ドルで、前年同期から15％増加した。 基本的1株当たり利益（当社株主に帰属する四半期純利益を加重平均普通株式数で除して算出）2025年3月31日に終了した3ヶ月間において0.21ドルであり、前年同期から5%増加した。 EBITDA1は営業利益に減価償却費および無形資産の減損損失を加えた値で算出され25百万ドルで、前年同期から3％減少した。EBITDAマージン1は2025年第1四半期で52％となり、2024年第1四半期の46％から増加した。 ROE（当社株主に帰属す...
-
Retractable Technologies, Inc. Results for the Period Ended March 31, 2025
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $8.3 million for the first three months of 2025 and an operating loss of $4.7 million for the period, as compared to total net sales for the same period last year of $7.6 million and an operating loss of nearly $3.0 million. The differences in operating losses are largely due to an increase in tariffs and additional period costs related to increased domestic production activities....